Clinical Trials Logo
  1. Home
  2. Ankylosing Spondylitis
  3. NCT05987111
  4. Details
NCT05987111 Clinical Trial

Pilates in Ankylosing Spondylitis

Ankylosing Spondylitis Clinical Trial

Official title:
Comparison of Efficacy of Two Different Pilates Exercise Methods in Individuals With Ankylosing Spondylitis: A Randomized Controlled Study

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05987111
Other study ID # Exercise
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2, 2022
Est. completion date February 10, 2023

Study information
Verified date August 2023
Source Pamukkale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was planned to examine and compare the effectiveness of two different pilates exercise methods (mat pilates vs reformer pilates) in individuals with Ankylosing Spondylitis(AS).

Recruitment information / eligibility
Status Completed
Enrollment 20
Est. completion date February 10, 2023
Est. primary completion date December 15, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - Being in the age range of 20-65, using stable medication for at least 3 months, being sedentary (Not regularly participating in exercise activities for the past 3 months). Exclusion Criteria: - the presence of cardiovascular, pulmonary, orthopedic and neurological problems, another rheumatic disease, being pregnant, inability to participate in at least 75% of the exercises.

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Pilates
Pilates exercises were applied twice a week for 4 weeks in both groups. The sessions were supervised by an Australian Physiotherapy and Pilates Institute (APPI) certified physiotherapist as 5 minutes of warm-up, 45 minutes of exercise and 5 minutes of cool-down periods.

Locations
Country Name City State
Turkey Usak University Usak Merkez

Sponsors (1)
Lead Sponsor Collaborator
Pamukkale University

Country where clinical trial is conducted

Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary Bath Ankylosing Spondylitis Metrology Index This index consists of 5 measurements: cervical rotation, tragus to wall distance, lumbar side flexion, modified Schober's, intermalleolar distance. 10 minutes
Primary Bath Ankylosing Spondylitis Disease Activity Index BASDAI consists of 6 questions evaluating the patient's level of weakness/fatigue, spinal pain, joint pain/swelling and sensitivity to touch, and duration of morning stiffness in the last week. 5minutes
Primary Bath Ankylosing Spondylitis Functional Index (BASFI) This scale, which evaluates the functional limitation of AS patients in activities of daily living, consists of 10 questions. 5 minutes
Primary Ankylosing Spondylitis Quality of Life Questionnaire This questionnaire, which evaluates disease-specific quality of life, consists of 18 questions 5 minutes
Primary Maastrich Ankylosing Spondylitis Enthesitis Score Its validity and reliability were defined to evaluate enthesopathy and peripheral joint involvement. 5minutes
Primary Multidimensional Assessment of Fatigue Scale MAF scale evaluates the level of fatigue during daily activities in the last week. 5 minutes
Primary Biopsychosocial Questionnaire (BETY-BQ) The BETY-BQ evaluates the biopsychosocial status of patients with rheumatic diseases. 10minutes
See also
  Status Clinical Trial Phase
Terminated NCT02685904 - A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis Phase 3
Completed NCT02186873 - A Study of Golimumab in Participants With Active Ankylosing Spondylitis Phase 3
Completed NCT01668004 - The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Phase 4
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01934933 - Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Phase 4
Not yet recruiting NCT04875299 - Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
Completed NCT02763111 - Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis Phase 2
Completed NCT02758782 - NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis Phase 4
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT01750528 - Prevalence and Progression of Periodontitis in Ankylosing Spondylitis N/A
Completed NCT01463189 - Web-based Support to Manage Arthritis Pain Phase 2
Completed NCT01091675 - Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs Phase 3
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Recruiting NCT00747578 - Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan N/A
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Completed NCT00715091 - Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Phase 4
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00367211 - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers. Phase 3
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4